Form 8-K - Current report:
SEC Accession No. 0001193125-26-210291
Filing Date
2026-05-07
Accepted
2026-05-07 07:04:16
Documents
11
Period of Report
2026-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krro-20260507.htm   iXBRL 8-K 52708
2 EX-99.1 krro-ex99_1.htm EX-99.1 150115
3 GRAPHIC img174420225_0.jpg GRAPHIC 11939
  Complete submission text file 0001193125-26-210291.txt   351879

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT krro-20260507.xsd EX-101.SCH 32946
14 EXTRACTED XBRL INSTANCE DOCUMENT krro-20260507_htm.xml XML 4884
Mailing Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141
Business Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 26950791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)